Document Detail

The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients.
MedLine Citation:
PMID:  20860069     Owner:  NLM     Status:  In-Data-Review    
Cardiotoxicity has been feared as a potential side effect of imatinib therapy. Studies with short-term follow-up failed to identify an excess of cardiac events, but longer-term observations are needed to more definitely exclude this adverse effect. This study was designed to assess the cardiac effects of imatinib in patients under long-term treatment. We included 90 chronic myeloid leukaemia (CML) patients under imatinib therapy for a median treatment time of 3.3 years (mean age 48.9 ± 15.1 years). Patients underwent clinical evaluation, electrocardiography, echocardiography (two-dimensional, colour flow, tissue Doppler and strain imaging), brain natiuretic peptide (BNP) and troponin I measurements. Twenty healthy volunteers were included as a control group for strain measurements. The mean ejection fraction was 68 ± 7% and the median BNP level was 9.6 pg/ml (interquartile range [IQR] 5.7-17.0 pg/ml). Two patients had either an elevated BNP or a depressed ejection fraction (2.2%; 90%CI 0.9-6.8%). Most of troponin I measurements were lower than the detection limit, except for two patients. Longitudinal strain was similar to measurements in healthy controls. A weak relation was observed between log BNP and imatinib treatment duration and dose. There was no relation between these variables and left ventricle ejection fraction. In conclusion, matinib-related cardiotoxicity is an uncommon event in CML patients, even during long-term treatment. Therefore, its use should not be cause of great concern, and the usefulness of regular cardiac monitoring all patients while on imatinib therapy is questionable. Copyright © 2010 John Wiley & Sons, Ltd.
Milena S Marcolino; Eric Boersma; Nelma C D Clementino; Maria do Carmo P Nunes; Márcia M Barbosa; Maria Helena C R Silva; Marcel L Geleijnse; Antonio L Ribeiro
Related Documents :
20306889 - Usefulness of 6-minute walk test, plasma neurohumoral and cytokine activation in the as...
3486649 - Antithrombin, prekallikrein, and fibronectin levels in surgical patients.
15948099 - Nt-probnp in acute heart failure: correlation with invasively measured hemodynamic para...
18243859 - Amino-terminal pro-b-type natriuretic peptide testing and prognosis in patients with ac...
8357099 - Increased plasma endothelin levels in kawasaki disease: a possible marker for kawasaki ...
19675059 - Prevalence of chronic kidney disease in patients with suspected sleep apnoea.
24088309 - Long term outcome of the wallflex partially covered stent for unresectable malignant bi...
8273759 - Risk and benefit of additional aortocoronary bypass grafting in patients undergoing car...
21479879 - Functional outcomes in retrosigmoid approach microsurgery and gamma knife stereotactic ...
Publication Detail:
Type:  Journal Article     Date:  2010-09-22
Journal Detail:
Title:  Hematological oncology     Volume:  29     ISSN:  1099-1069     ISO Abbreviation:  Hematol Oncol     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-09-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8307268     Medline TA:  Hematol Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  124-30     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 John Wiley & Sons, Ltd.
School of Medicine, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity dis...
Next Document:  Deletion and duplication of 15q24: molecular mechanisms and potential modification by additional cop...